- Home
- GMM vs ATNM Comparison
GMM vs ATNM Comparison
Compare GMM & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- ATNM
- Stock Information
- Founded
- GMM 2017
- ATNM 2000
- Country
- GMM China
- ATNM United States
- Employees
- GMM N/A
- ATNM N/A
- Industry
- GMM
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- GMM
- ATNM Health Care
- Exchange
- GMM Nasdaq
- ATNM Nasdaq
- Market Cap
- GMM 61.9M
- ATNM 50.2M
- IPO Year
- GMM 2023
- ATNM N/A
- Fundamental
- Price
- GMM N/A
- ATNM N/A
- Analyst Decision
- GMM
- ATNM Strong Buy
- Analyst Count
- GMM 0
- ATNM 2
- Target Price
- GMM N/A
- ATNM $4.50
- AVG Volume (30 Days)
- GMM 699.8K
- ATNM 108.6K
- Earning Date
- GMM 08-18-2025
- ATNM 11-13-2025
- Dividend Yield
- GMM N/A
- ATNM N/A
- EPS Growth
- GMM N/A
- ATNM N/A
- EPS
- GMM 1.79
- ATNM N/A
- Revenue
- GMM $48,171,048.00
- ATNM N/A
- Revenue This Year
- GMM N/A
- ATNM N/A
- Revenue Next Year
- GMM N/A
- ATNM N/A
- P/E Ratio
- GMM $1.12
- ATNM N/A
- Revenue Growth
- GMM 41.74
- ATNM N/A
- 52 Week Low
- GMM $1.69
- ATNM $1.03
- 52 Week High
- GMM $10.50
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- GMM 45.28
- ATNM 45.01
- Support Level
- GMM $1.90
- ATNM $1.56
- Resistance Level
- GMM $2.04
- ATNM $1.64
- Average True Range (ATR)
- GMM 0.13
- ATNM 0.06
- MACD
- GMM 0.01
- ATNM -0.00
- Stochastic Oscillator
- GMM 42.89
- ATNM 23.08
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.